Floatz logo

Therapeutic Asset Ratings

6,369 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nivolumab
Metastatic Malignant Neoplasm In The Brain
Stanford UniversityP3B (62)
Nivolumab
Ovarian Carcinoma
Instituto do Cancer do Estado de São PauloP3B (62)
Nivolumab
Head And Neck Cancer
Fate TherapeuticsP3B (62)
Nivolumab
Liver Metastases
University of Wisconsin, MadisonP3B (62)
Nivolumab
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
ExelixisP3B (62)
Nivolumab
Primary Peritoneal Carcinoma
Regeneron PharmaceuticalsP3B (62)
PANITUMUMAB
Pancreatic Adenocarcinoma
SWOG Cancer Research NetworkP3B (62)
Pembrolizumab
Cervical Cancer
Merck Sharp & Dohme LLCP3B (62)
Pembrolizumab
Nonpapillary Renal Cell Carcinoma
City of Hope Medical CenterP3B (62)
Pembrolizumab
Esophageal Cancer
Essen BiotechP3B (62)
Pembrolizumab
Esophageal Squamous Cell Carcinoma
GV20 TherapeuticsP3B (62)
Pembrolizumab
Fallopian Tube Cancer
OncoC4, Inc.P3B (62)
Pembrolizumab
Hodgkins Lymphoma
Michael Spinner, MDP3B (62)
Pembrolizumab
Invasive Breast Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP3B (62)
Pembrolizumab
Lung Cancer
City of Hope Medical CenterP3B (62)
Pembrolizumab
Lung Disorder
Sarah GoldbergP3B (62)
Pembrolizumab
Metastatic Melanoma
Brown UniversityP3B (62)
Pembrolizumab
Metastatic Neoplasm
Mohammed MilhemP3B (62)
Pembrolizumab
Ovarian Carcinoma
Roswell Park Cancer InstituteP3B (62)
Pembrolizumab
PD-L1 Positive
Gilead SciencesP3B (62)
Pembrolizumab
Peritoneal Neoplasm
Seagen, a wholly owned subsidiary of PfizerP3B (62)
Pembrolizumab
Prostate Cancer
Icahn School of Medicine at Mount SinaiP3B (62)
Pembrolizumab
Small Cell Lung Carcinoma
GV20 TherapeuticsP3B (62)
pm8002
Small Cell Lung Carcinoma
Biotheus Inc.P3B (62)
pm8002
Triple-Negative Breast Carcinoma
Biotheus Inc.P3B (62)
Showing 726 to 750 of 6,369 assets
PreviousPage 30 of 255Next